Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), has released its financial report for the third quarter of 2024. The company reported revenues of RMB 939 million (USD 131.8 million) for the period, marking a 28.58% increase year-on-year. The net profit attributable to the parent company reached RMB 233 million (USD 32.4 million), representing a 42.18% increase year-on-year. Additionally, the total R&D investment saw significant growth, surging 54.07% to RMB 354 million (USD 49.7 million).
During the quarter, Sunshine Guojian made significant progress with its product pipeline. SSGJ-608, an anti-IL-17A monoclonal antibody (mAb), completed a pivotal Phase III study in moderate to severe plaque psoriasis and enrolled patients for Phase II studies in ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr axSpA). The anti-IL-5 mAb, 610, is enrolling subjects for a Phase III study in severe eosinophilic asthma. The anti-IL-4Rα mAb, 611, initiated a Phase III study in moderate to severe atopic dermatitis, a Phase III study in chronic sinusitis with nasal polyps, and a Phase II study in adolescents with moderate to severe atopic dermatitis. The anti-IL-1β mAb, 613, began a Phase III study in acute gouty arthritis and a Phase II study in the intermittent period of gouty arthritis. Lastly, 626, a BDCA2-targeted mAb, which was previously cleared for studies in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) in the US, is under trial review in China for these indications.
The financial results and pipeline updates reflect Sunshine Guojian’s commitment to advancing innovative therapies and underscores the company’s growth trajectory in the biopharmaceutical sector.- Flcube.com
